BR112022001161A2 - Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida - Google Patents

Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Info

Publication number
BR112022001161A2
BR112022001161A2 BR112022001161A BR112022001161A BR112022001161A2 BR 112022001161 A2 BR112022001161 A2 BR 112022001161A2 BR 112022001161 A BR112022001161 A BR 112022001161A BR 112022001161 A BR112022001161 A BR 112022001161A BR 112022001161 A2 BR112022001161 A2 BR 112022001161A2
Authority
BR
Brazil
Prior art keywords
methyl
methoxyazetidin
dihydropyridin
dioxol
methylthio
Prior art date
Application number
BR112022001161A
Other languages
English (en)
Inventor
Alamelu Banda
S Gehling Victor
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of BR112022001161A2 publication Critical patent/BR112022001161A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

formas cristalinas de 7-cloro-2-(4- (3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil4-(metiltio)-2-oxo-1,2-di-hidropiridin-3- il)metil)benzo[d][1,3]dioxol-5-carboxamida. a presente invenção refere-se a uma forma cristalina 1 de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida que é útil como moduladora da atividade de enzimas modificadoras de histona metila. a presente invenção também fornece composições farmaceuticamente aceitáveis compreendendo a forma cristalina e métodos de uso das referidas composições no tratamento de vários distúrbios.
BR112022001161A 2019-07-24 2020-07-23 Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida BR112022001161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962878012P 2019-07-24 2019-07-24
PCT/US2020/043178 WO2021016414A1 (en) 2019-07-24 2020-07-23 Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide

Publications (1)

Publication Number Publication Date
BR112022001161A2 true BR112022001161A2 (pt) 2022-06-07

Family

ID=72047059

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001161A BR112022001161A2 (pt) 2019-07-24 2020-07-23 Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Country Status (14)

Country Link
US (1) US20220251073A1 (pt)
EP (1) EP4003532A1 (pt)
JP (1) JP2022541630A (pt)
KR (1) KR20220041129A (pt)
CN (1) CN114450279B (pt)
AU (1) AU2020316073A1 (pt)
BR (1) BR112022001161A2 (pt)
CA (1) CA3148447A1 (pt)
CL (1) CL2022000175A1 (pt)
CO (1) CO2022001482A2 (pt)
IL (1) IL289972A (pt)
MX (1) MX2022000931A (pt)
PE (1) PE20220562A1 (pt)
WO (1) WO2021016414A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2023135564A1 (ko) * 2022-01-14 2023-07-20 동화약품주식회사 1,3-벤조다이옥솔 유도체 화합물 및 이를 포함하는 약학적 조성물
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2024015566A1 (en) 2022-07-15 2024-01-18 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of at-rich interactive domain-containing protein 1a (arid1a) mutated cancers
CN115403040B (zh) * 2022-08-11 2023-08-01 中国地质大学（北京） 一种可通过光辐射调控导热系数的偶氮苯聚合物表面修饰的金刚石纳米粒子及其制备方法
WO2024038115A1 (en) 2022-08-17 2024-02-22 Morphosys Ag Therapy comprising anti-cd19 antibody and ezh2 modulators
WO2024076663A1 (en) 2022-10-06 2024-04-11 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of brca1-associated protein (bap1) mutated cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2806859T1 (sl) * 2012-01-25 2019-11-29 Vertex Pharma Formulacije 3-(6-(1-(2.2-difluorobenzo(d)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
ME02730B (me) * 2013-02-11 2017-10-20 Constellation Pharmaceuticals Inc Modulatori enzima koji modifikuju metil, njihove kompozicije i upotreba
PT3121175T (pt) * 2014-03-17 2020-03-05 Daiichi Sankyo Co Ltd Derivados de 1,3-benzodioxol como inibidores de ezh1 e/ou ezh2
US10577350B2 (en) * 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
TW201831181A (zh) * 2017-01-19 2018-09-01 日商第一三共股份有限公司 用以用於治療ｈｔｌｖ－１相關脊髓病之醫藥組成物
UA127357C2 (uk) * 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання

Also Published As

Publication number Publication date
CN114450279A (zh) 2022-05-06
MX2022000931A (es) 2022-05-03
JP2022541630A (ja) 2022-09-26
US20220251073A1 (en) 2022-08-11
CN114450279B (zh) 2024-07-09
CO2022001482A2 (es) 2022-03-18
CA3148447A1 (en) 2021-01-28
KR20220041129A (ko) 2022-03-31
WO2021016414A1 (en) 2021-01-28
AU2020316073A1 (en) 2022-02-17
PE20220562A1 (es) 2022-04-13
IL289972A (en) 2022-03-01
CL2022000175A1 (es) 2022-09-20
EP4003532A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
BR112022001161A2 (pt) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
AU2018236800B2 (en) DNA-PK inhibitors
BR112019005595A2 (pt) compostos e métodos para modulação de ido e tdo, e indicações para os mesmos
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
SG10201903579SA (en) Indole carboxamides compounds useful as kinase inhibitors
BR112016024472A8 (pt) composto, medicamento, e, uso de um composto
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
BR112016001289A2 (pt) pancreatina de alta atividade (ha-pancreatina), composição farmacêutica de alta potência, processo para preparação da ha-pancreatina com atividade de lipase específica de, pelo menos, cerca de 120 ui usp/mg e método de tratamento de um paciente que apresenta uma condição fisiológica associada à insuficiência enzimática pancreática
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
EP3870170A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES
PE20160519A1 (es) Compuestos de tetrahidrocarbozol y carbozol carboxamida sustituidos utiles como inhibidores de cinasa
BR112017007545A2 (pt) derivados de carbazol
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
ECSP11011076A (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma